Clinical Research Center, Kyoto Medical Center, Kyoto, Japan.
Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan.
Clin Immunol. 2020 Aug;217:108455. doi: 10.1016/j.clim.2020.108455. Epub 2020 May 30.
In this study, we measured immunoglobulin free light chains (FLC), a biomarker of inflammation in the sera of patients with heart failure due to myocarditis.
FLC kappa and FLC lambda were assayed in stored serum samples from patients with heart failure with myocarditis from the US myocarditis treatment trial by a competitive-inhibition multiplex Luminex® assay.
The median concentration of circulating FLC kappa/lambda ratio was significantly lower in the sera from patients with heart failure with myocarditis than in healthy controls, and FLC kappa/lambda ratio had good diagnostic ability for identification of heart failure with myocarditis. Further, FLC kappa/lambda ratio was an independent prognostic factor for overall survival, and allowed creation of three prognostic groups by combining with N-terminal pro-B-type natriuretic peptide.
This study suggests that FLC kappa/lambda ratio is a promising biomarker of heart failure with myocarditis.
本研究测定了心肌炎性心力衰竭患者血清中的免疫球蛋白游离轻链（FLC），这是一种炎症生物标志物。
采用竞争抑制型多重 Luminex®分析法检测美国心肌炎治疗试验中心肌炎性心力衰竭患者储存的血清样本中的 FLCκ和 FLCλ。
与健康对照组相比，心肌炎性心力衰竭患者血清中循环 FLCκ/λ 比值的中位数明显降低，且 FLCκ/λ 比值对识别心肌炎性心力衰竭具有良好的诊断能力。此外，FLCκ/λ 比值是总生存的独立预后因素，并可与 N 末端脑钠肽前体结合，将患者分为三个预后组。
本研究表明 FLCκ/λ 比值是心肌炎性心力衰竭有前途的生物标志物。
